Seminars in Oncology Nursing
Volume 23 , Pages S10-S16 , November 2007

Overcoming Treatment Challenges in Advanced Breast Cancer

  • Barbara Harkins

      Affiliations

    • Corresponding Author InformationAddress correspondence to Barbara Harkins, RN, MN, National Surgical Adjuvant Breast and Bowel Project, Protocol Development & Management, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212-5234
    • ,
  • Charles E. Geyer Jr.

References 

  1. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319:1–11
  2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(suppl 2):21–26
  3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  5. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–4274
  6. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21:2889–2895
  7. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer. 2003;4:120–125
  8. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5:52–62
  9. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer. 2005;6:325–329
  10. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  11. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. [abstract] J Clin Oncol. 2005;23(suppl 16):3004
  12. Schwartz G, Chu QSC, Hammond LA, et al. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol. 2004;23:3070
  13. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  14. Geyer CE, Martin A, Newstat M, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol. 2007;25(suppl 18):1035

 The development of this article was based on a presentation given by C. Geyer at the 2006 Oncology Nursing Society's 7th Annual Institutes of Learning; Dr Geyer received an honorarium through an educational grant from GlaxoSmithKline.

PII: S0749-2081(07)00090-3

doi: 10.1016/j.soncn.2007.10.003

Seminars in Oncology Nursing
Volume 23 , Pages S10-S16 , November 2007

Article Tools

* Image Usage & Resolution